PDCD1 and non-small cell lung carcinoma: ICIs that target the PD-1/PD-L1 axis have been effective in solid tumors, such as non-small cell lung cancer (NSCLC), with high levels of PD-L1 expression and active lymphocytic infiltrates (80).